What the Peptide Skeptics Agree On: Topol, Attia & Saladino

Peptides are having their loudest moment ever — and not everyone is cheering. Three credible, very different voices have publicly pumped the brakes: Eric Topol, the cardiologist and one of the most-cited medical researchers alive; Peter Attia, the longevity physician; and Paul Saladino, the contrarian animal-based MD. They don't agree on much in general — but on peptides, their critiques converge in a way worth paying attention to.

This is a synthesis of where the skeptics line up. It's educational, not medical advice, and where a view is one person's interpretation rather than settled science, we say so.

The three critiques, in one line each

Eric Topol — "The Peptide Craze" (his Ground Truths essay reviewing ~15 injectable peptides plus NAD+). His blunt conclusion: "there is no evidence from randomized trials in humans that any of these peptides provide the benefits that are advocated" — with GLP-1s as the standout exception.
Peter Attia — AMA #83, "Peptides: evaluating the science, safety, and hype." His frame: peptides are a legitimate, powerful class of therapeutics — but that legitimacy is confined to a narrow subset, and most biohacking-culture peptides don't clear the bar.
Paul Saladino — "Peptides Explained." His thesis: "there is no biological free lunch." (We covered his full breakdown here.)

Here's where they actually meet.

It's worth noting these aren't fringe contrarians. Topol is one of the most-cited physician-researchers alive and edits a widely-read science newsletter; Attia is a mainstream longevity clinician who actually uses parts of this toolkit; Saladino is the provocateur of the three. And the same skeptical read shows up from neutral science communicators too — McGill University's Office for Science and Society titled its BPC-157 piece "No Proof Required," and the independent research site Examine reaches the same "promising in rodents, unproven in humans" conclusion. When the cheerleaders and the critics agree on the evidence and only disagree on the vibe, the evidence is the signal.

1. The human-trial gap is the core problem

All three keep returning to the same hole: for the popular non-GLP-1 peptides, there are almost no randomized controlled trials in humans. Topol's "The Peptide Craze" reviewed roughly 15 injectable peptides plus NAD+ and landed on a single sentence: there's no randomized-human-trial evidence that any of them deliver the advertised benefits. BPC-157 is the recurring case study — animal data from essentially one Croatian research group, and human evidence that amounts to a couple of tiny, uncontrolled case series and an n=2 IV safety report (see the BPC-157 research page for the full roster, including the one real Phase 2 trial that's still recruiting). TB-500 (research) has even less — essentially zero human data. Topol's point is the sharpest: rodent and in-vitro results, however consistent, are not evidence of human benefit, and consistency within one lab's body of work isn't the same as independent replication. Attia's framework is the most structured: separate the FDA-approved therapeutics from the loosely-regulated biohacking peptides, then judge each on the strength — and replication — of its actual human data, rather than promoting or dismissing the category wholesale.

2. GLP-1s are the agreed-upon exception

None of the three is anti-peptide wholesale, and all three carve out the GLP-1s. Semaglutide, tirzepatide, and the rest have tens of thousands of patients and hard outcome data behind them — they are the proof that a peptide can deliver. The skepticism is aimed at everything riding the GLP-1 wave's coattails without the same evidence. (See semaglutide and retatrutide for the trials that earned that exception.) Even here, all three flag the same caveats: muscle loss, regain after stopping, and lifelong dependency.

3. The gray-market quality problem is real and data-backed

This is the least disputed point of all, because it isn't an opinion — it's measured. Saladino cites the 2024 study that found online "semaglutide" testing at single-digit purity, and the 38-state-attorney-general letter to the FDA about a "national ecosystem of counterfeit, contaminated, and research-grade peptides." The shared conclusion: with anonymous "research only" powder, you frequently don't know what's in the vial — which means even a peptide with real promise can't be evaluated honestly when the product itself is a coin flip.

4. The open cancer/safety questions

Topol and Saladino both land on the same unresolved worry for the recovery peptides: BPC-157 and TB-500 promote angiogenesis — the growth of new blood vessels — partly by upregulating VEGF and its receptor VEGFR2. Here's why that's a flag rather than a feature: a whole class of cancer drugs (anti-angiogenics like bevacizumab) works by blocking angiogenesis, because solid tumors can't grow past a few millimeters without recruiting their own blood supply. The theoretical concern is the mirror image — chronically dialing angiogenesis up could, in principle, help feed a tumor you don't yet know you have. Saladino, who did his college molecular-biology research on angiogenesis signaling, leans on exactly this. The growth-hormone secretagogues raise a parallel worry through a different door: more GH means more IGF-1, and elevated IGF-1 is epidemiologically linked to higher cancer rates.

The honest framing all three use: no one is claiming these compounds cause cancer, and there's no documented case of a peptide doing so. The point is narrower and harder to dismiss — the risk plausibly depends on dose, duration, age, and whether you already have an occult tumor, and the long-term human safety data to rule it out simply doesn't exist. Stacking (BPC-157 + TB-500 + a GH secretagogue, say) compounds the unknown by sending several pro-growth signals at once.

Where they DON'T agree

Honesty cuts both ways, so it's worth flagging where the skeptics diverge — because it tells you which parts are evidence and which are worldview:

Saladino's prescription is ideological. His answer to almost everything is "eat single-ingredient real food," rooted in his carnivore/animal-based philosophy. That's a strongly-held personal position, not a clinical consensus, and Topol and Attia don't share it.
Attia is the most permissive. He's genuinely open to the legitimate subset and uses peptides in his own practice within that subset — his message is "be discerning," not "avoid."
Topol is the most absolutist on the evidence bar: until there's a randomized human trial, he treats the benefit claims as unproven, full stop.

What the skeptics are NOT saying

It's easy to read all this as "peptides are useless." That's not the argument. The shared message is more precise and more useful: most non-GLP-1 peptides are interesting hypotheses that haven't been tested in humans yet — and a few of them (melanotan for melanoma risk, anything from an unverified gray-market source) carry real downside. The skeptics aren't telling you peptides can't work. They're telling you to know exactly which tier of evidence you're standing on for each specific compound, and to demand proof of what's actually in the vial.

That's the same lens this whole site is built around. Every compound mentioned here has a research page that foregrounds the trial sizes, the mechanism, and the honest evidence limits — so you can judge each one the way the skeptics would.

This article synthesizes publicly available commentary for educational purposes and is not affiliated with or endorsed by Eric Topol, Peter Attia, or Paul Saladino. Their views are summarized and attributed; where a position is personal opinion rather than established science, that's noted. Not medical advice.